Calcify Uremic Arteriolopathy Drug
Calcify Uremic Arteriolopathy Drug

Calcify Uremic Arteriolopathy Drug Market – Alkem Labs, LUPIN, Hope Pharmaceuticals, Sanifit, BSN medical, Sun Pharmaceutical Industries Ltd

Calcific uremic arteriolopathy is also known as calciphylaxis is serious, rare and progressive disease mainly seen in patients with end stage renal kidney disease and also prevalent in skeletal calcifications occurs when the calcium start accumulating in the small blood vessels of the fat and  skin tissues. It results in blood coagulation, painful skin ulcers and risk of infections.

Gobal Calcify Uremic Arteriolopathy Drug Market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth.

According to the statistics published in the Orphanet, it was estimated the overall prevalence of this disease was 0.5 in 10,000. Huge financial support from the government and increase in strategic alliances between the companies are key factors for market growth.

Key Market Players Amgen Inc, Alkem Labs, LUPIN, Hope Pharmaceuticals, Sanifit, BSN medical,  Sun Pharmaceutical Industries Ltd, Cipla Inc, Mylan N.V. Teva Pharmaceutical Industries Ltd, Zydus Cadila and others.

Request for Sample Report @

Market Drivers

  • Increase patient population of kidney disease  worldwide is drive the market
  • Increase special designation from the regulatory authorities is boosting the market growth
  • Emergence of drugs used to treat complication associated with calciphylaxis is accelerating the market growth
  • Huge financial support to the researchers for developing novel intervention is enhancing the market growth

Segmentation: Global Calcify Uremic Arteriolopathy Drug Market

By Causes

  • Peripheral Arterial Disease
  • Cardiovascular Disease (CVD)
  • Others

By Treatment Type

  • Skin Wound Management
  • Surgery
  • Medication

By Drugs

  • Cinacalcet
  • Bisphosphonates
  • Others

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retailers
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Browse Full Report with Details TOC @

Key Developments in the Market:

In May 2019, Alkem Labs received ANDA approval from the FDA for cinacalcet hydrochloride tablet, calcium-sensing receptor agonist for the treatment of hypercalcemia including calciphylaxis in adult patients with chronic kidney disease (CKD). The approval of cinacalcet hydrochloride tablet will provide cost effective treatment to the patients with calciphylaxis.

In June 2018, Hope Pharmaceuticals has initiated the enrollment for 111 Canadian patients to participate in the phase III trial (CALISTA) double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Sodium Thiosulfate for the treatment of calciphylaxis-related pain. This drug also received Orphan Drug designation from the European Union for the treatment of calciphylaxis. If approved, it will provide hope to the patients with caliphylaxis throughout the Canada.

Competitive Analysis:

global calcify uremic arteriolopathy drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global calcify uremic arteriolopathy drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry before Buying @

his Calcify Uremic Arteriolopathy Drug report will help to develop market strategies by understanding the market trends shaping and driving Calcify Uremic Arteriolopathy Drug market.  It helps to understand the future market competition in the market. In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufactures and the market as whole. It also analyzes key emerging trends and their impact on present and future development. The Calcify Uremic Arteriolopathy Drug report identifies significant trends and factors driving or inhibiting the market growth. The Calcify Uremic Arteriolopathy Drug report analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

About Us

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

About Data Bridge Market Research 13737 Articles
Hi, I am Ravi Kumar, a Blogger, Freelancer, SEO Consultant, an Internet Marketer, I am a research analyst who loves to evaluate data relating to Manufacturing industry, Management of companies and enterprises, Finance and insurance, Wholesale trade, Management, scientific, and technical consulting services

Leave a Reply

Your email address will not be published.